KRTX

KarTX

Schizophrenia

Phase 3 (Enrollment)

Exp Date

Q4 2020

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: KarTX in Schizophrenia - Phase 3 Enrollment

  • ClinicalTrial.gov (NCT03697252): A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-1)


WHAT IS THE NEXT CATALYST EVENT?

  • Phase 3 Enrollment


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • Q4 2020


PRIOR DATA

PRESS RELEASES




PRESENTATION

MECHANISM OF ACTION

  • KarXT, a proprietary oral modulator of muscarinic cholinergic receptors, is Karuna’s lead product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an FDA-approved muscarinic antagonist that does not appreciably cross the blood-brain-barrier, to preferentially stimulate muscarinic receptors in the central nervous system (CNS). This novel product candidate, if approved, has the potential to usher in a new treatment paradigm and dramatically impact patients with schizophrenia and other psychotic disorders by providing a differentiated mechanism of action relative to current D2 dopamine and serotonin receptor-targeting antipsychotic drugs.

MARKET

  • Across studies that use household-based survey samples, clinical diagnostic interviews, and medical records, estimates of the prevalence of schizophrenia and related psychotic disorders in the U.S. range between 0.25% and 0.64%.

  • Estimates of the international prevalence of schizophrenia among non-institutionalized persons is 0.33% to 0.75%.

  • Learn more at the National Institute of Mental Health

Updated by HC

KRTX, Schizophrenia, KarTX, mental health, mental disorder, brain, neurology, 

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon